Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Catalyst Pharmaceuticals Inc CPRX

Healthcare Biotechnology
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for... see more

Recent & Breaking News (NDAQ:CPRX)

Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024

GlobeNewswire 3 days ago

Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day

GlobeNewswire March 28, 2024

Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium

GlobeNewswire March 27, 2024

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)

GlobeNewswire March 13, 2024

Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference

GlobeNewswire March 5, 2024

Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire February 28, 2024

Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE

GlobeNewswire February 27, 2024

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical's VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

GlobeNewswire February 21, 2024

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

GlobeNewswire February 14, 2024

Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering

GlobeNewswire January 9, 2024

Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

GlobeNewswire January 5, 2024

Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire January 4, 2024

Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma

GlobeNewswire December 18, 2023

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies

GlobeNewswire December 5, 2023

Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions

GlobeNewswire December 4, 2023

Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference

GlobeNewswire November 16, 2023

Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update

GlobeNewswire November 8, 2023

Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®

GlobeNewswire November 2, 2023

Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo

GlobeNewswire October 30, 2023

Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

GlobeNewswire October 26, 2023